976 results on '"Narita, Yoshitaka"'
Search Results
52. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas
53. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR
54. Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for brain tumors
55. Karnofsky Performance Status and Quality of Life in Patients with Relapsed or Refractory Primary CNS Lymphoma from a Phase I/II Study of Tirabrutinib
56. Consulting a neurosurgeon upon initial medical assessment reduces the time to the first surgery and potentially contributes to improved prognosis for glioblastoma patients
57. Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice
58. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis
59. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
60. Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review
61. Assessment of clinical and functional outcome in patients with cancer and acute ischemic stroke
62. Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network
63. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
64. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
65. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas
66. Abstract 1506: Decoding multi-omics genetic profiling reveals heterogeneity in adult pan-gliomas
67. Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
68. Supplementary Tables from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
69. Data from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
70. Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
71. Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
72. Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
73. Supplementary Figures SF1-SF8 from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
74. Supplementary Table from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
75. Supplementary Material and Methods from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
76. Data from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
77. A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis
78. Awake Surgery for a Patient With Glioblastoma and Severe Aphasia: Case Report
79. Consultation with a neurosurgeon upon initial medical assessment is associated with improved prognosis of glioblastoma patients
80. Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults
81. Prognostic factors of brain metastases from colorectal cancer
82. Publisher Correction: DNA demethylation is associated with malignant progression of lower-grade gliomas
83. DNA demethylation is associated with malignant progression of lower-grade gliomas
84. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study
85. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors
86. Male sex and presence of preoperative symptoms are associated with early recurrence of WHO grade I meningiomas after surgical resection: analysis from the nationwide Brain Tumor Registry of Japan
87. ACT-8 A RANDOMIZED PHASE III STUDY OF HYPOFRACTIONATED RADIOTHERAPY COMBINED WITH TEMOZOLOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: JCOG1910 (AGEDGLIO-PIII)
88. COT-16 NATION-WIDE LANDSCAPE OF GENOMIC ANALYSIS OF ADULT CENTRAL NERVOUS SYSTEM TUMORS IN JAPAN
89. GEN-9 WHOLE GENOME SEQUENCING ANALYSIS REVEALS STRUCTURAL VARIANTS CONTRIBUTE TO TUMOR EVOLUTION IN IDH-MUTANT GLIOMA
90. ACT-13 DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: A FIRST-IN-HUMAN, PHASE 1 STUDY
91. NQPC-10 IMPACT OF HEALTH-RELATED QOL (HRQOL) IN THE FIRST SIX MONTHS AFTER SURGERY ON LONG-TERM POSTOPERATIVE GENERAL HEALTH STATUS IN GLIOMA PATIENTS
92. MET-10 A SINGLE CENTER RETROSPECTIVE ANALYSIS OF AWAKE CRANIOTOMY FOR METASTATIC BRAIN TUMOR
93. PEDT-18 PHASE I/II TRIAL OF OP-10 (ONC201) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE MIDLINE GLIOMA
94. GEN-8 COMPREHENSIVE WHOLE GENOME SEQUENCING ANALYSIS ELUCIDATES STRUCTURAL VARIANTS IN MEDULLOBLASTOMA
95. BT-4 PROGNOSIS OF HISTOLOGICALLY DIAGNOSED GRADE 2-3 IDH-WILD TYPE DIFFUSE GLIOMAS TREATED WITH RADIATION AND TEMOZOLOMIDE
96. GEN-10 WHOLE GENOME LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE
97. RT-8 POST-IRRADIATION COURSE OF GLIOMAS OF THALAMUS AND BRAINSTEM
98. ACT-19 A REPORT OF PHASE I PART OF PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFORMIN AND TEMOZOLOMIDE FOR GLIOBLASTOMA
99. PEDT-10 PHASE II TRIAL OF PATHOLOGY-BASED THREE-GROUP TREATMENT STRATIFICATION FOR PATIENTS WITH CNS GERM CELL TUMORS: A LONG-TERM FOLLOW-UP STUDY
100. PEDT-12 NATIONWIDE LANDSCAPE OF GENOMIC ANALYSIS OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.